MedTrace Logo

Long-term Follow up of Patient With Anti-GABAbr Antibodies Associated-encephalitis.

NCT05741619 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2023-02-23

No results posted yet for this study

Summary

First described in 2010, GABA-B-receptor antibodies-associated encephalitis is a disease with a severe vital and functional prognosis. Indeed, functional status is mostly altered by encephalitis and it induced consequences while vital status is mostly engaged by cancer very often associated in the course of the disease, mostly small-cell lung cancer (SCLC).

While knowledge is growing on clinical features at each stage of the disease, long-term outcome data is still lacking even if known to be pejorative.

In this study, we aimed to describe long-term follow up of all patients who were diagnosed a GABAb-receptor antibodies-associated encephalitis in the French Paraneoplastic Neurological Syndrome Reference Center until now.

Conditions

  • Autoimmune Encephalitis

Interventions

OTHER

Long-term outcome

Autonomy, physical examination, behavioural disorders

Sponsors & Collaborators

  • Hospices Civils de Lyon

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2022-06-01
Completion
2022-09-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05741619 on ClinicalTrials.gov